5 November 2025 | 3:27PM CST Equity Research China Healthcare: Insulin 3Q25 wrap-up: Ample room for domestic substitution in insulin analogs After two rounds of VBP, China's insulin industry has seen a major opportunity for domestic substitution, and the two companies we cover in this segment have continued to deliver strong revenue growth. According to our tracked database Pharmcube, the localization rates of three representative insulin analogs - insulin glargine, insulin aspart, and insulin aspart premix ...